Why?15 May 2025 07:49
So i pop in occasionally to monitor progress and consider opportunity as i know (as stated previously) if this treatment works* there’s potentially, massive sp increase in the offing.
From an investment standpoint, is It not therefore, the most important factor to consider here , is it/will it work
*Work meaning;
A commercially successful treatment for AML
I doubt there’s much disagreement on that being many years off.
So in the interim the more initial data shared on progress, the more enlightened investors and potential investors will be.
When i proposed, knowing the present state of health of P1 is a very important question to raise in an attempt to best consider progress, the circus clowns here mount their little fire engines and swarm around in a pathetic attempt to smother out the question.
Why do they feel the need to do that i wonder!?
From the company perspective, keeping the detail of initial efficacy data undisclosed could be as some have suggested here, that it’s commercially sensitive. Is it though?
Well i would agree that if the data is bad or mediocre, then yes but if it’s good then no i don’t think it is.
Is there a significant downside to all, including potential suitors being made aware of good efficacy news?
So in short, wanting to know more of the early efficacy signals and if P1 has CR or not, i respectfully suggest IS the most important question right now.
Now those same circus clowns and some new (for supposed credibility), will again mount their little fire engines and swarm to smother the question with a myriad of deflective , abusive and discrediting posts.
I’ll set aside an hour to read Haywire’s lengthy scientific smoke and mirrors diatribe.
AIMO
Sign In
Follow the stocks
